



PHE Weekly National Influenza Report

Summary of UK surveillance of influenza and other seasonal respiratory illnesses

20 April 2017 – Week 16 report (up to week 15 data)

This report is published weekly on the [PHE website](#). For further information on the surveillance schemes mentioned in this report, please see the [PHE website](#) and the [related links](#) at the end of this document.

| [Summary](#) | [Community surveillance](#) | [GP consultation rates](#) | [Hospitalisations](#) | [All-cause mortality](#) | [Microbiological surveillance](#) | [Vaccination](#) | [International](#) | [Acknowledgements](#) | [Related links](#) |

Summary


During week 15 (ending 16 April 2017), influenza activity continues to decrease across all indicators. The Department of Health has issued an [alert](#) on the prescription of antiviral medicines by GPs.

- [Community influenza surveillance](#)
 - Through the GP In Hours Syndromic Surveillance system, GP consultations for influenza-like illness (ILI) were decreasing in week 15.
 - Eight new acute respiratory outbreaks have been reported in the past 7 days. All eight outbreaks were from care homes, with no test results available.
- [Overall weekly influenza GP consultation rates across the UK](#)
 - Due to bank holidays in week 15 (ending 16 April 2017), GP surgeries were only open for four days – data should therefore be interpreted with caution.
 - In week 15, the overall weekly influenza-like illness (ILI) GP consultation rate was 2.5 per 100,000 in England compared to 3.8 per 100,000 in the previous week. This is below the baseline threshold of 14.3 per 100,000 for this season. In the devolved administrations, ILI rates are low and remained similar to the previous week.
- [Influenza-confirmed hospitalisations](#)
 - In week 15, there were four admissions to ICU/HDU with confirmed influenza (three influenza A(unknown subtype) and one influenza B) were reported across the UK (125/156 Trusts in England) through the USSS mandatory ICU scheme with a rate of 0.01 per 100,000 compared to 0.01 per 100,000 in the previous week.
 - In week 15, there were five hospitalised confirmed influenza cases (three influenza A(H3N2), one influenza A(not subtyped) and one influenza B) reported through the USSS sentinel hospital network (13 NHS Trusts across England), with a rate of 0.10 per 100,000, compared to 0.08 per 100,000 in the previous week.
 - No confirmed influenza admissions have been reported from the six Severe Respiratory Failure centres in the UK in week 15.
- [All-cause mortality data](#)
 - In week 15 2017, no statistically significant excess all-cause mortality by week of death was seen through the EuroMOMO algorithm in England and in the devolved administrations.
- [Microbiological surveillance](#)
 - Four samples tested positive for influenza (four influenza B) through the UK GP sentinel swabbing schemes, with an overall positivity of 14.8% compared to 34.9% in week 14.
 - 15 influenza positive detections were recorded through the DataMart scheme (eight influenza A(H3N2), four influenza A(not subtyped) and three influenza B) in week 15. The overall positivity was at 1.6% in week 15 compared to 3.3% in week 14, which is below the threshold for 2016/17 season of 8.6%. The highest age-specific positivities were seen in the 65+ year olds (3.0%).
- [Vaccination](#)
 - Provisional data from the fifth monthly collection of influenza vaccine uptake by frontline healthcare workers show 63.4% were vaccinated by 28 February 2017, compared to 50.8% vaccinated in the previous season by 29 February 2016. The report provides uptake at Trust level.
 - Up to week 04 2017, in 85.0% of GP practices reporting weekly to Immform, the provisional proportion of people in England who had received the 2016/17 influenza vaccine in targeted groups was as follows: 48.5% in under 65 years in a clinical risk group, 44.9% in pregnant women and 70.5% in 65+ year olds. In 88.1% of GP practices reporting to Immform, the provisional proportion of children in England who had received the 2016/17 influenza vaccine was as follows: 39.0% in all 2 year olds, 41.6% in all 3 year olds and 33.8% in all 4 year olds.
 - Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients up to 31 January 2017 has been published. The [report](#) provides uptake at national, Area Team (AT), Clinical Commissioning Group (CCG) and by Local Authority (LA) levels.
 - Provisional [data](#) from the fourth monthly collection of influenza vaccine uptake for children of school years 1, 2 and 3 age show the provisional proportion of children in England who received the 2016/17 influenza vaccine via school, pharmacy or GP practice by 31 January 2017 in targeted groups was as follows: 57.6% in children of school Year 1 age (5-6 years); 55.3% in children of school Year 2 age (6-7 years); 53.3% in children of school Year 3 age (7-8 years).
- [International situation](#)
 - Globally, influenza activity in the temperate zone of the northern hemisphere continued to decrease. Influenza activity remained low in the temperate zone of the southern hemisphere. Worldwide, influenza A(H3N2) and B viruses were predominant, with an increased proportion of influenza B viruses detected in recent weeks.
 - The [vaccine recommendation for the 2017-2018 northern hemisphere](#) influenza season has been made.


Through the GP In Hours Syndromic Surveillance system, GP consultations for influenza-like illness (ILI) were decreasing in week 15. Eight new acute respiratory outbreaks were reported in the past 7 days.

- PHE Real-time Syndromic Surveillance
 - During week 15, GP consultations for influenza-like illness were decreasing.
 - For further information, please see the syndromic surveillance [webpage](#).

- Acute respiratory disease outbreaks
 - Eight new acute respiratory outbreaks have been reported in the past 7 days. All eight outbreaks were from care homes, with no test results available.
 - Outbreaks should be recorded on HPZone and reported to the local Health Protection Teams and Respscisc@phe.gov.uk.




- FluSurvey
 - Internet-based surveillance of influenza-like illness in the general population is undertaken through the FluSurvey. A project run jointly by PHE and the London School of Hygiene and Tropical Medicine.
 - The overall ILI rate (all age groups) for week 15 was 16.8 per 1,000 (30/1,781 people reported at least 1 ILI), with the 20-44 years age group reporting a higher rate of 21.9 per 1,000.
 - If you would like to become a participant of the FluSurvey project please do so by visiting the <https://flusurvey.org.uk/en/accounts/register/> website for more information.



In week 15, the overall weekly influenza-like illness GP consultation rate is low and is below the baseline threshold in England. In the devolved administrations, ILI rates are low and remained similar to the previous week.

- Influenza/Influenza-Like-Illness (ILI)



Northern Ireland

- The Northern Ireland ILI rate is low and similar to the previous week at 15.4 per 100,000 in week 15 compared to 14.9 per 100,000 in week 14. This is below the baseline threshold (47.9 per 100,000).
- The highest rates were seen in <1 year olds (53.3 per 100,000) and 65-74 year olds (28.2 per 100,000).

Wales

-The Welsh ILI rate is low and similar to the previous week at 1.8 per 100,000 in week 15 compared to 2.9 per 100,000 in week 14 (Figure 3). This is below the baseline threshold (10.3 per 100,000).

- The highest rates were seen in the 75+ year olds (3.0 per 100,000) and 45-64 year olds (2.5 per 100,000).

Scotland

-The Scottish ILI rate is low and similar to the previous week at 4.9 per 100,000 in week 15 compared to 5.1 per 100,000 in week 14 (Figure 3). This remains below the baseline threshold (36.1 per 100,000).


-The highest rates were seen in <1 year olds (10.3 per 100,000) and 45-64 year olds (6.9 per 100,000).

RCGP (England and Wales)

- The weekly ILI consultation rate through the RCGP surveillance is at 2.5 per 100,000 in week 15 compared to 3.8 per 100,000 in week 14. This is below the baseline threshold (14.3 per 100,000) (Figure 4*). By age group, the highest rates were seen in 45-64 year olds (4.1 per 100,000) and 15-44 year olds/75+ year olds (2.5 per 100,000 respectively).

- Due to bank holidays in week 15 (ending 16 April 2017) should therefore be interpreted with caution.

**The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe.*



GP In Hours Syndromic Surveillance System (England)


-The weekly ILI consultation rate through the GP In Hours Syndromic Surveillance system is at 2.5 per 100,000 in week 15 (Figure 5).

Figure 5 represents a map of GP ILI consultation rates in week 15 across England by Local Authorities, using influenza-like illness surveillance thresholds.

Thresholds are calculated using a standard methodology for setting ILI thresholds across Europe (the "Moving Epidemic Method" (MEM)) and are based on six previous influenza seasons (excluding the 2009/10 H1N1 pandemic)

-For further information, please see the syndromic surveillance [webpage](#).

Figure 5: Map of GP ILI consultation rates in Week 15



Influenza confirmed hospitalisations

[Back to top](#)



In week 15, there were four admissions to ICU/HDU with confirmed influenza (three influenza A(unknown subtype) and one influenza B) reported through the USISS mandatory ICU/HDU surveillance scheme across the UK (125 Trusts). Five hospitalised confirmed influenza cases (three influenza A(H3N2), one influenza A(not subtyped) and one influenza B) were reported through the USISS sentinel hospital network across England (13 Trusts).

A national mandatory collection (USISS mandatory ICU scheme) is operating in cooperation with the Department of Health to report the number of confirmed influenza cases admitted to Intensive Care Units (ICU) and High Dependency Units (HDU) and number of confirmed influenza deaths in ICU/HDU across the UK. A confirmed case is defined as an individual with a laboratory confirmed influenza infection admitted to ICU/HDU. In addition a sentinel network (USISS sentinel hospital network) of acute NHS trusts is established in England to report weekly laboratory confirmed hospital admissions. Further information on these systems is available through the [website](#). Please note data in previously reported weeks are updated and so may vary by week of reporting

- Number of new admissions and fatal confirmed influenza cases in ICU/HDU (USISS mandatory ICU scheme), UK (week 15)

- In week 15, there were four admissions to ICU/HDU with confirmed influenza (three influenza A(unknown subtype) and one influenza B) reported across the UK (125/156 Trusts in England) through the USISS mandatory ICU scheme, with a rate of 0.01 per 100,000 compared to a rate of 0.01 per 100,000 in week 14 (Figures 6 and 7). One death was reported to have occurred in week 15.


A total of 1,072 admissions (590 influenza A(unknown subtype), 332 influenza A(H3N2), 90 influenza A(H1N1)pdm09 and 60 influenza B) and 134 confirmed deaths have been reported since week 40 2016.



- USISS sentinel weekly hospitalised confirmed influenza cases, England (week 15)

- In week 15, there were five hospitalised confirmed influenza cases (three influenza A(H3N2), one influenza A(not subtyped) and one influenza B) reported through the USISS sentinel hospital network from 13 NHS Trusts across England (Figure 8), a rate of 0.10 per 100,000 compared to 0.08 per 100,000 in the previous week.

A total of 1,536 hospitalised confirmed influenza admissions (1,021 influenza A(H3N2), 419 influenza A(not subtyped), 70 influenza B and 26 influenza A(H1N1pdm09)) have been reported since week 40 2016.



- USISS Severe Respiratory Failure Centre confirmed influenza admissions, UK (week 15)

- In week 15, there were no confirmed influenza admissions reported from the six Severe Respiratory Failure (SRF) centres in the UK. There have been four confirmed influenza admissions (one influenza A(H3N2) and three influenza A(unknown subtype)) reported since week 40 2016.

All-cause mortality data

[| Back to top |](#)

In week 15 2017 in England, no statistically significant excess all-cause mortality by week of death was seen through the EuroMOMO algorithm in England. In the devolved administrations, no significant excess all-cause mortality was observed in week 15.

Seasonal mortality is seen each year in the UK, with a higher number of deaths in winter months compared to the summer. Additionally, peaks of mortality above this expected higher level typically occur in winter, most commonly the result of factors such as cold snaps and increased circulation of respiratory viruses, in particular influenza. Weekly mortality surveillance presented here aims to detect and report acute significant weekly excess mortality above normal seasonal levels in a timely fashion. Excess mortality is defined as a significant number of deaths reported over that expected for a given point in the year, allowing for weekly variation in the number of deaths. The aim is not to assess general mortality trends or precisely estimate the

excess attributable to different factors, although some end-of-winter estimates and more in-depth analyses (by age, geography etc.) are undertaken.

- All-cause death registrations, England and Wales

- In week 14 2017, an estimated 9,939 all-cause deaths were registered in England and Wales (source: [Office for National Statistics](#)). This is a decrease compared to the 10,027 estimated death registrations in week 13 2017.

- Excess all-cause mortality by age group, England, Wales, Scotland and Northern Ireland

- In week 15 2017 in England, no excess mortality by week of death above the upper 2 z-score threshold was seen overall, by age group or subnationally, after correcting ONS disaggregate data for reporting delay with the standardised EuroMOMO algorithm (Table 1). This data is provisional due to the time delay in registration; numbers may vary from week to week.

- In the devolved administrations, no significant excess mortality above the threshold was observed in week 15 (Table 2).

Table 1: Excess mortality by age group, England*

Age group (years)	Excess detected in week 15 2017?	Weeks with excess in 2016/17
<5	x	-
5-14	x	-
15-64	x	52-02
65+	x	45, 51-05

* Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold


Table 2: Excess mortality by UK country, for all ages*

Country	Excess detected in week 15 2017?	Weeks with excess in 2016/17
England	x	52-05
Wales	x	03
Scotland	x	46,50-51,01,05
Northern Ireland	x	50-51,01-03,05,07-08

* Excess mortality is calculated as the observed minus the expected number of deaths in weeks above threshold

NB. Separate total and age-specific models are run for England which may lead to discrepancies between Tables 1 + 2

Figure 9: Excess mortality in all ages by week of death, EuroMOMO, England



Microbiological surveillance

[| Back to top |](#)

In week 15 2017, four samples tested positive for influenza (four influenza B) through the UK GP sentinel schemes with an overall positivity of 14.8%. 15 positive detections were recorded through the DataMart scheme (eight influenza A(H3N2), four influenza A(not subtyped) and three influenza B) with a positivity of 1.6% in week 15.

- Sentinel swabbing schemes in England (RCGP) and the Devolved Administrations

-In week 15, four samples tested positive for influenza (four influenza B) through the UK GP sentinel swabbing schemes, with an overall positivity of 14.8% compared to 34.9% in week 14 (Table 3).

Since week 40 2016, 940 samples (757 influenza A(H3N2), 60 influenza A(unknown subtype), 3 influenza A(H1N1)pdm09 and 120 influenza B) have tested positive for influenza through this scheme.




Table 3: Sentinel influenza surveillance in the UK

Week	England	Scotland	Northern Ireland	Wales
11	2/45 (4.4%)	10/53 (18.9%)	2/7 (-)	0/9 (-)
12	2/28 (7.1%)	10/43 (23.3%)	2/4 (-)	0/2 (-)
13	0/12 (-)	7/39 (18%)	0/1 (-)	0/4 (-)
14	0/5 (-)	8/26 (30.8%)	7/10 (70%)	0/2 (-)
15	0/2 (-)	1/19 (5.3%)	3/6 (-)	0/0 (-)

NB. Proportion positive omitted when fewer than 10 specimens tested

- Respiratory DataMart System (England)

In week 15 2017, out of the 935 respiratory specimens reported through the Respiratory DataMart System, 15 samples (1.6%) were positive for influenza (eight influenza A(H3N2), four influenza A(not subtyped) and three influenza B) (Figure 10), which is below the MEM threshold for this season of 8.6%. The highest positivity by age group was seen in the 65+ year olds (3.0%)(Figure 11). The overall positivity for RSV remained low at 0.7% in week 15. Positivity for rhinovirus positivity was at 14.7% in week 15. Positivity for adenovirus and parainfluenza remained at an increased level at 6.5% and 10.1% respectively in week 15. Positivity for human metapneumovirus (hMPV) decreased to 1.3% in week 15.



**The Moving Epidemic Method has been adopted by the European Centre for Disease Prevention and Control to calculate thresholds for GP ILI consultations for the start of influenza activity in a standardised approach across Europe. The threshold to indicate a likelihood of influenza community circulation for Datamart % positive as calculated through the Moving Epidemic Method is 8.6% in 2016/17.*

- Virus characterisation

PHE characterises the properties of influenza viruses through one or more tests, including genome sequencing (genetic analysis) and haemagglutination inhibition (HI) assays (antigenic analysis). These data are used to compare how similar the currently circulating influenza viruses are to the strains included in seasonal influenza vaccines, and to monitor for changes in circulating influenza viruses. The interpretation of genetic and antigenic data sources is complex due to a number of factors, for example, not all viruses can be cultivated in sufficient quantity for antigenic characterisation, so that viruses with sequence information may not be able to be antigenically characterised as well. Occasionally, this can lead to a biased view of the properties of circulating viruses, as the viruses which can be recovered and analysed antigenically, may not be fully representative of majority variants, and genetic characterisation data does not always predict the antigenic characterisation

Since the start of the 2016/17 winter influenza season in week 40 2016, the PHE Respiratory Virus Unit has characterised four A(H1N1)pdm09 influenza viruses: one both genetically and antigenically and three antigenically. The A(H1N1)pdm09 virus genetically characterised belongs in the genetic subgroup 6B.1, which was the predominant genetic subgroup in the 2015/16 season. The three viruses antigenically analysed are similar to the A/California/7/2009 Northern Hemisphere 2016/17 (H1N1)pdm09 vaccine strain. Genetic characterisation of 318 A(H3N2) influenza viruses since week 40 showed that they all belong to genetic subclade 3C.2a, with 158 belonging to a cluster within this genetic subclade designated as 3C.2a1. The Northern Hemisphere 2016/17 influenza A(H3N2) vaccine strain A/HongKong/4801/2014 belongs in genetic subclade 3C.2a. This seasons A(H3N2) viruses are difficult to cultivate, and only 24 influenza A(H3N2) viruses have been isolated and antigenically characterised since week 40 2016, representing a minority of the detections, indicating the bias in antigenic data. The viruses antigenically analysed are similar to the A/HongKong/4801/2014 Northern Hemisphere 2016/17 A(H3N2) vaccine strain. Of the 24 antigenically characterised viruses, eight isolates have also been genetically characterised, with all belonging in genetic group 3C.2a, and six also belonging in the recently emerged 3C.2a1 cluster. Sixteen influenza B viruses have been analysed genetically since week 40/2015; 13 have been characterised as belonging to the B/Yamagata/16/88-lineage and 3 belonging to the B/Victoria/2/1987-lineage. Nineteen influenza B viruses have been isolated and antigenically characterised since week 40 2016. Fourteen viruses were characterised as belonging to the B/Yamagata/16/88-lineage and were antigenically similar to B/Phuket/3073/2013, the influenza B/Yamagata-lineage component of 2016/17 Northern Hemisphere quadrivalent vaccine. Five viruses were characterised as belonging to the B/Victoria/2/87-lineage and were antigenically similar to B/Brisbane/60/2008, the influenza B/Victoria-lineage component of 2016/17 Northern Hemisphere trivalent and quadrivalent vaccines.

- Antiviral susceptibility

Influenza positive samples are screened for mutations in the virus neuraminidase gene known to confer oseltamivir and/or zanamivir resistance. Additionally, testing of influenza A (H1N1)pdm09, A(H3N2), and influenza B virus isolates for neuraminidase inhibitor susceptibility (oseltamivir and zanamivir) is performed at PHE-RVU using a functional assay. The data summarized below combine the results of both testing methods. The samples tested are routinely obtained for surveillance purposes, but diagnostic testing of patients suspected to be infected with neuraminidase inhibitor-resistant virus is also performed.

Since week 40 2016, 305 influenza A(H3N2) have been tested for oseltamivir susceptibility; 300 are fully susceptible. 286 of the 305 were also tested for zanamivir susceptibility with 280 being fully susceptible. Four A(H3N2) viruses have been detected with an R292K amino acid substitution, which causes resistance to oseltamivir and a reduction in susceptibility to zanamivir, and one A(H3N2) virus with an E119V amino acid substitution was detected, causing resistance to oseltamivir but not tested for zanamivir susceptibility. All four R292K cases and the E119V case have been identified in patients with underlying medical conditions with some exposure to oseltamivir. Nine influenza A(H1N1)pdm09 and 17 influenza B (Yamagata) viruses have been tested for oseltamivir susceptibility and all were fully susceptible. One of the nine influenza A(H1N1)pdm09 virus and all 17 influenza B (Yamagata) virus have been tested for zanamivir susceptibility and all were fully susceptible.

- Antimicrobial susceptibility

-Table 4 shows in the 12 weeks up to 16 April 2017, the proportion of all lower respiratory tract isolates of *Streptococcus pneumoniae*, *Haemophilus influenzae*, *Staphylococcus aureus*, MRSA and MSSA tested and susceptible to antibiotics. These organisms are the key causes of community acquired pneumonia (CAP) and the choice of antibiotics reflects the British Thoracic Society empirical guidelines for management of CAP in adults.

Table 4: Antimicrobial susceptibility surveillance in lower respiratory tract isolates, 12 weeks up to 16 April 2017, E&W

Organism	Antibiotic	Specimens tested (N)	Specimens susceptible (%)
<i>S. pneumoniae</i>	Penicillin	4,096	90
	Macrolides	4,636	83
	Tetracycline	4,400	86
<i>H. influenzae</i>	Amoxicillin/ampicillin	19,575	68
	Co-amoxiclav	20,784	88
	Macrolides	7,661	10
	Tetracycline	20,469	98
<i>S. aureus</i>	Methicillin	6,680	90
	Macrolides	7,429	67
MRSA	Clindamycin	422	36
	Tetracycline	597	80
MSSA	Clindamycin	3,610	77
	Tetracycline	5,592	93


*Macrolides = erythromycin, azithromycin and clarithromycin

Vaccination

[| Back to top |](#)


- Up to week 04 2017 in 85.0% of GP practices reporting weekly to Immform, the provisional proportion of people in England who had received the 2016/17 influenza vaccine in targeted groups was as follows, with vaccination activity starting earlier than last season (Figure 13):
 - 48.5% in under 65 years in a clinical risk group
 - 44.9% in pregnant women
 - 70.5% in 65+ year olds

Figure 13: Cumulative weekly influenza vaccine uptake by target group in England



- In 2016/17, all two-, three- and four-year-olds continue to be eligible for flu vaccination. In addition, the programme has been extended to children of school years 1, 2 and 3 age. Up to week 04 2017 in 88.1% of GP practices reporting weekly to Immform, the provisional proportion of children in England who had received the 2016/17 influenza vaccine in targeted groups was as follows (Figure 14):
 - 39.0% in all 2 year olds
 - 41.6% in all 3 year olds
 - 33.8% in all 4 year olds

Figure 14: Cumulative weekly influenza vaccine uptake by target group in England



- Provisional data from the fifth monthly collection of influenza vaccine uptake by frontline healthcare workers show 63.4% were vaccinated by 28 February 2017 from 98.9% of Trusts, compared to 50.8% vaccinated in the previous season by 29 February 2016. The report provides uptake at Trust level.
- Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients up to 31 January 2017 show that in 97.3% of all GP practices in England responding to the main GP survey, the proportion of people in England who received the 2016/17 influenza vaccine was as follows:
 - 48.7% in under 65 years in a clinical risk group
 - 44.8% in pregnant women
 - 70.4% in 65+ year olds
- Provisional data from the fourth monthly collection of influenza vaccine uptake in GP patients up to 31 January 2017 show that in 96.7% of all GP practices in England responding to the child GP survey, the proportion of people in England who received the 2016/17 influenza vaccine was as follows:
 - 38.9% in all 2 year olds
 - 41.5% in all 3 year olds
 - 33.9% in all 4 year olds
- Provisional data from the fourth monthly collection of influenza vaccine uptake for children of school years 1, 2 and 3 age (from a sample of 100% of all Local Authorities in England) show the proportion of children in England who received the 2016/17 influenza vaccine via school, pharmacy or GP practice by 31 January 2017 in targeted groups was as follows:
 - 57.6% in children of school Year 1 age (5-6 years)
 - 55.3% in children of school Year 2 age (6-7 years)
 - 53.3% in children of school Year 3 age (7-8 years)

International Situation

[| Back to top |](#)

Influenza activity in the temperate zone of the northern hemisphere continued to decrease. Influenza activity remained low in the temperate zone of the southern hemisphere. Worldwide, influenza A(H3N2) and B viruses were predominant, with an increased proportion of influenza B viruses detected in recent weeks.

- [Europe](#) updated on 14 April 2017 (Joint ECDC-WHO Influenza weekly update)

In week 14/2017, influenza activity across the region continued to be at low level with 39 countries of 41 reporting low intensity of influenza activity. However, only 10 of 42 countries reported no geographic spread indicating that influenza viruses are still circulating.

This was the fourth week during the season that the proportion of type B viruses exceeded the proportion of type A viruses in sentinel detections. However, the overall number of type B virus detections remained low.

For week 14/2017, 116 (17%) of 669 sentinel specimens tested positive for influenza viruses. Of these, 94% were type B and 6% type A viruses. The proportion of type B viruses commonly increases in the second half of an influenza season. Of 7 subtyped A viruses, 6 were A(H3N2) and one was A(H1N1)pdm09 virus. The lineage of 30 influenza B viruses was determined, of which 18 were in B/Yamagata and 12 in B/Victoria lineages.

For week 14/2017, of 9 countries that conduct surveillance of hospitalized laboratory-confirmed influenza cases, 4 countries reported 12 cases, 8 in intensive care units (ICU) and 4 in other wards. Of the patients admitted to ICU, 6 were infected with influenza type A viruses (1 - influenza A not subtyped, 5 - A(H3N2)) and 2 with influenza B viruses. In other wards, 3 cases were infected with A(H3N2) and 1 with influenza B virus.

For week 14/2017, 1,303 specimens from non-sentinel sources (such as hospitals, schools, non-sentinel primary care facilities, nursing homes and other institutions) tested positive for influenza viruses. Of these, 34% were type A (with 99% of the subtyped viruses being A(H3N2)), and 66% type B. The increase in proportion of type B viruses corresponds to the data seen in sentinel detections; however the number of B viruses detected remained low and similar to that seen in the previous 6 weeks.

The majority of participating European countries have had a marked excess in all-cause mortality since the end of 2016, in particular among the elderly aged 65 years and above. Currently, the mortality level seems to have decreased again. This season's excess mortality coincided with circulation of influenza A(H3N2), which usually leads to increased mortality among the elderly.

- [United States of America](#) updated on 14 April 2017 (Centre for Disease Control report)

During week 14, influenza activity decreased but remained elevated in the United States.

The most frequently identified influenza virus type reported by public health laboratories during week 14 was influenza B. The percentage of respiratory specimens testing positive for influenza in clinical laboratories decreased.

A cumulative rate for the season of 59.4 laboratory-confirmed influenza-associated hospitalizations per 100,000 population was reported.

Nationwide during week 14, the proportion of outpatient visits for influenza-like illness (ILI) was 2.6%, which is above the national baseline of 2.2%.

- [Canada](#) updated on 14 April 2017 (Public Health Agency report)

Overall, influenza activity is slowly declining in Canada.

In week 14, influenza B accounted for a greater proportion of influenza laboratory detections, hospitalizations and outbreaks compared to the previous week.

Influenza activity due to influenza B is slowly increasing but is low compared to the same time period in the previous two seasons.

Influenza A activity is decreasing; however, influenza A continues to be the most common type of influenza affecting Canadians.

The majority of laboratory detections, hospitalizations and deaths have been among adults aged 65+ years.

- [Global influenza update](#) updated on 17 April 2017 (WHO website)

Influenza activity in the temperate zone of the northern hemisphere continued to decrease. Influenza activity remained low in the temperate zone of the southern hemisphere. Worldwide, influenza A(H3N2) and B viruses were predominant, with an increased proportion of influenza B viruses detected in recent weeks.

In North America, influenza activity decreased slightly in Canada and the United States of America; influenza A(H3N2) viruses predominated with slight increases in influenza B virus detections. In Mexico, influenza activity decreased with all seasonal influenza subtypes detected.

In Europe, influenza activity continued to decrease to low levels, with detections of predominantly influenza B viruses in Northern and Eastern Europe. Influenza-like illness (ILI) and severe acute respiratory infection (SARI) indicators were generally low or below baseline.

In Central Asia, ILI and SARI activities decreased but an update on influenza virus detections was not available.

In East Asia, influenza activity continued to be reported with all seasonal influenza subtypes detected. In Western Asia, influenza activity continued to decrease with influenza B viruses predominant.

In Southern Asia, influenza activity continued to be reported although it appeared to be decreasing. In Bhutan, ILI levels and influenza activity increased in recent weeks, with influenza A(H3N2) and B viruses circulating. In South East Asia, influenza activity remained low.

In Northern Africa, low influenza activity was reported in Tunisia, with influenza A(H3N2) and B viruses predominant.

In East and West Africa, low influenza activity was reported in recent weeks, with influenza A(H1N1)pdm09, A(H3N2) and B viruses co-circulating.

In the Caribbean and Central America countries, respiratory virus activity remained low.

In tropical South America, influenza and other respiratory virus activities remained low. Respiratory syncytial virus (RSV) activity remained elevated in Colombia.

In the temperate zone of the Southern Hemisphere, influenza activity was at inter-seasonal levels. In Chile, ILI activity increased to seasonal threshold in recent weeks, consistent with past seasonal trends.

Based on FluNet reporting, the WHO GISRS laboratories tested more than 118,962 specimens between 20 March 2017 and 02 April 2017. 19,667 were positive for influenza viruses, of which 9,791 (49.8%) were typed as influenza A and 9,876 (50.2%) as influenza B. Of the sub-typed influenza A viruses, 924 (26.2%) were influenza A(H1N1)pdm09 and 2,609 (73.8%) were influenza A(H3N2). Of the characterized B viruses, 784 (65%) belonged to the B-Yamagata lineage and 423 (35%) to the B-Victoria lineage

The vaccine recommendation for the 2017-2018 northern hemisphere influenza season has been made. It is recommended that trivalent vaccines for use in the 2017-2018 northern hemisphere influenza season contain the following:

- an A/Michigan/45/2015 (H1N1)pdm09-like virus;
- an A/Hong Kong/4801/2014 (H3N2)-like virus; and
- a B/Brisbane/60/2008-like virus.

It is recommended that quadrivalent vaccines containing two influenza B viruses contain the above three viruses and a B/Phuket/3073/2013-like virus. The full report can be found [here](#).

- [Avian Influenza](#) latest update on 05 April 2017 (WHO website)

Influenza A(H5) viruses

Between [14 February and 16 March 2017](#), two new laboratory-confirmed human case of influenza A(H5N1) virus infection was reported to WHO from Egypt. Avian influenza A(H5N1) viruses are enzootic in poultry in Egypt.

Since 2003, a total of 858 laboratory-confirmed cases of human infection with avian influenza A(H5N1) virus, including 453 deaths, have been reported to WHO from 16 countries.

Influenza A(H5) subtype viruses have the potential to cause disease in humans and thus far, no human cases, other than those with influenza A(H5N1) and A(H5N6) viruses, have been reported to WHO. According to reports received by the World Organisation for Animal Health (OIE), various influenza A(H5) subtypes continue to be detected in birds in West Africa, Europe and Asia. There have also been numerous detections of influenza A(H5N8) viruses in wild birds and domestic poultry in several countries in Africa, Asia and Europe since June 2016, and influenza A(H5N5) in wild birds in Europe. For more information on the background and public health risk of these viruses, please see the WHO assessment of risk associated with influenza A(H5N8) virus [here](#).

Influenza A(H7N9)

On [7 April 2017](#), the National Health and Family Planning Commission of China (NHFPC) notified WHO of 14 additional laboratory-confirmed cases of human infection with avian influenza A(H7N9) virus in mainland China.

On [31 March 2017](#), the National Health and Family Planning Commission of China (NHFPC) notified WHO of 17 additional laboratory-confirmed cases of human infection with avian influenza A(H7N9) virus in mainland China.

A total of 1,378 laboratory-confirmed human infections with avian influenza A (H7N9) virus, including at least 489 deaths, have been reported through IHR notification since early 2013.

- [Middle East respiratory syndrome coronavirus \(MERS-CoV\)](#) latest update on 04 April 2017

On [21 March 2017](#) the national IHR focal point of Qatar reported one additional case of Middle East Respiratory Syndrome Coronavirus (MERS-CoV).

Between [23 February and 16 March 2017](#) the national IHR focal point of Saudi Arabia reported 18 additional cases of Middle East Respiratory Syndrome (MERS) including two fatal cases. Four deaths among previously reported MERS cases were also reported (case numbers 1, 4, 5 and 7 in the Disease Outbreak News published on 10 March 2017).

Up to 19 April 2017, a total of four cases of Middle East respiratory syndrome coronavirus, MERS-CoV, (two imported and two linked cases) have been confirmed in the UK. On-going surveillance has identified 954 suspect cases in the UK that have been investigated for MERS-CoV and tested negative.

Globally, since September 2012, WHO has been notified of 1,936 laboratory-confirmed cases of infection with MERS-CoV, including at least 690 related deaths. Further information on management and guidance of possible cases is available [online](#). The latest ECDC MERS-CoV risk assessment can be found [here](#), where it is highlighted that risk of widespread transmission of MERS-CoV remains low.

Acknowledgements

[| Back to top |](#)

This report was prepared by the Influenza section, Respiratory Diseases Department, Centre for Infectious Disease Surveillance and Control, Public Health England. We are grateful to all who provided data for this report including the RCGP Research and Surveillance Centre, the PHE Real-time Syndromic Surveillance team, the PHE Respiratory Virus Unit, the PHE Modelling and Statistics unit, the PHE Dept. of Healthcare Associated Infection & Antimicrobial Resistance, PHE regional microbiology laboratories, Office for National Statistics, the Department of Health, Health Protection Scotland, National Public Health Service (Wales), the Public Health Agency Northern Ireland, the Northern Ireland Statistics and Research Agency, QSurveillance[®] and EMIS and EMIS practices contributing to the QSurveillance[®] database.

Related links

[| Back to top |](#)

Weekly consultation rates in national sentinel schemes

- [Sentinel schemes operating across the UK](#)
- [RCGP scheme](#)
- Northern Ireland surveillance ([Public Health Agency](#))
- Scotland surveillance ([Health Protection Scotland](#))
- Wales surveillance ([Public Health Wales](#))
- [Real time syndromic surveillance](#)
- MEM threshold [methodology paper](#) and [UK pilot paper](#)

Community surveillance

- [Outbreak reporting](#)
- [FluSurvey](#)
- [MOSA](#)

Disease severity and mortality data

- [USISS](#) system
- [EuroMOMO](#) mortality project

Vaccination

- Seasonal influenza vaccine programme ([Department of Health Book](#))
- Childhood flu programme information for healthcare practitioners ([Public Health England](#))
- 2016/17 Northern Hemisphere seasonal influenza vaccine recommendations ([WHO](#))